Merz Pharma

hideThis article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (March 2021) (Learn how and when to remove this template message) This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (April 2020) (Learn how and when to remove this template message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help by replacing them with more appropriate citations to reliable, independent, third-party sources. (March 2021) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Merz Pharma GmbH & Co. KGaA.

Type	Private
Industry	Pharmaceuticals
Founded	09 March 1908
Headquarters	Frankfurt am Main
Key people	Andreas Krebs, Chairman, Philip Burchard, Chief Executive Officer
Revenue	€1,024.4 million (2017/2018)
Number of employees	3,151
Website	www.merz.com

Merz Pharma GmbH & Co. KGaA is a privately-held pharmaceutical company based in Frankfurt, Germany with affiliates across Europe, as well as the US, Canada, Mexico, Brazil and Asia Pacific and regional headquarters in Singapore and North Carolina, USA.

The company is active in research, development and distribution of products in the areas of aesthetic medicine and neurologically induced movement disorders. In German-speaking countries, the Merz consumer products business, Merz Consumer Care, is a provider of health, wellness and beauty products with its tetesept ^[1] and Merz Spezial^[2] brands.

Today, Merz’s global businesses are focused on the areas of medical aesthetics and neurotoxin therapy, supported by regional brands in both the prescription medicine and consumer health and beauty sectors. Key brands in the Merz Aesthetics portfolio include Belotero, Radiesse, Cellfina, Ultherapy, Botulinum Toxin and Neocutis (US only).^[3]

History[]

The company was founded in 1908 in Frankfurt, Germany by a 24-year old chemist named Friedrich Merz, and is still owned by the fourth generation of the Merz family.^[4]

1908 – Company founded

1911 – Introduction of first topical contraceptive Patentex

1953 – Launch of anti-wrinkle moisturizing cream Placentubex

1964 – Development of Merz Spezial Dragees from 18 different active ingredients

1965 – Introduction of tetesept bath medicine^[5]

1968 – Launch of Placentubex Foaming Mask

2002 – Introduction of Memantine for the treatment of Alzheimer’s disease

2005 – Merz launches a uniquely purified Botulinum Toxin

2010 – Acquisition of Bioform and its flagship product RADIESSE

2013 – Acquisition of Anteis and its range of dermal fillers, Belotero

2013 – Acquisition of Swiss skincare company Neocutis^[6]

2014 – Acquisition of the Ulthera System, the first ultrasound platform device with FDA clearance

2015 – Launch of Radiesse (+) Lidocaine in the US market

2015 – Establishment of Asia Pacific regional Headquarters in Singapore

2016 – Acquisition of ON Light Sciences with its flagship product DeScribe

2016 – Launch of the Cellfina System in the US, minimally-invasive cellulite treatment

2018 – Launch of Belotero Lips^[7]

2019 – Launch of Belotero Revive^[8]

2020 – Reorganization into three businesses: Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care^[9]

References[]

External links[]

• merz.com
• https://merzaesthetics.com/